Korean J Gastroenterol.
2000 Jun;35(6):806-814.
Lamivudine Rescue from the Accelerating Course of Chronic Hepatitis B
Abstract
- Acute aggravation of chronic hepatitis B is life-threatening, but there has been no acceptable treatment modality except for liver transplantation. Here, we report the effectiveness and safety of lamivudine in treating chronic hepatitis B of acute accelerating course. Three patients with chronic hepatitis B and one patient with liver cirrhosis due to hepatitis B were enrolled. All the cases showed hyperbilirubinemia and was in acute accelerating course. After the beginning of lamivudine treatment, HBV DNA in serum became undetectable in 2-6 weeks, and serum levels of aspartate aminotransferase and alanine aminotransferase became normal in 3 months in all cases. In two of them, HBeAg became negative at 7 weeks and 6 months after therapy, respectively. Lamivudine treatment in these patients was generally well tolerated. Lamivudine was safe and effective in treating chronic hepatitis B of accelerating course.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Lamivudine therapy for type B chronic hepatitis in Korea
- Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
- The Efficacy of Lamivudine in Korean Patients with Chronic Hepatitis B
- The management and treatment of chronic hepatitis B in Korean children
- Lamivudine and interferon combination therapy in chronic type B hepatitis
